This content is machine translated GLP-1-RA and dual GLP-1/GIP agonists. Tackling obesity – not only diabetics benefit from the effects While glucagon-like peptide (GLP)-1 receptor agonists have been successfully used in the treatment of diabetes for some time, there are now agents that activate not only the GLP-1 receptor but...…
View Post 4 min This content is machine translated Type 2 diabetes “Swiss Diabetes Guide” – digital tool supports physicians in drug selection The treatment options for type 2 diabetes mellitus are very complex. In addition to the large number of new active ingredients on the market, the scientific data base is constantly...…
View Post 2 min This content is machine translated Glucagon-like peptide 1 (GLP1) analogues The future of diabetes management has begun Diabetes does not hurt – one would almost like to add “unfortunately”. This is because the number of unreported cases of affected patients is still high. Possible late effects of...…
View Post 4 min This content is machine translated GLP-1 receptor agonists (GLP-1-RA) Type 2 diabetics benefit from dulaglutide in several ways The ADA/EASD guidelines recommend individualized therapy choices for type 2 diabetics. GLP-1 receptor agonists not only improve glycemic control, but also support weight loss, reduce the risk of cardiovascular disease,...…
View Post 4 min This content is machine translated GLP-1 receptor agonists Jack of all trades in the fight against type 2 diabetes GLP-1 receptor agonists (RA) have been used in the treatment of diabetic patients since 2005. For patients, their introduction was a milestone, as GLP-1 RAs have the great advantage of...…
View Post 4 min This content is machine translated Diabetes mellitus type 2 New Swiss guidelines support cardiovascular disease control The treatment of type 2 diabetes mellitus has undergone a transformation in recent years with the approval of new drug classes. The focus is no longer on pure glycemic control,...…